Saturday, August 1

Browsing: AntiPD1Progressed

Survivors

RP1/Nivolumab Shows OS Benefit in Anti-PD-1-Progressed Melanoma

By NewsCancerJune 1, 20260

Deep and durable responses were noted with vusolimogene oderparepvec (RP1) plus nivolumab (Opdivo) for patients with advanced melanoma who had…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.